Certified Registered Nurse Anesthetist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meredith Sobers

Nurse Anesthetist, Certified Registered Norfolk, VA Certified Registered Nurse Anesthetist

NPI 1982993804 CMS profile 11043517

600 Gresham Dr, Norfolk, VA 23507

Open in the dashboard

General payments

$4,425

197 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Sobers of Norfolk, VA is reported in the CMS Open Payments database as having received $4,425 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Anesthetist, Certified Registered profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,691 59
2024 General $1,151 58
2023 General $876 44
2022 General $602 30
2021 General $105 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Sobers
  • Nurse Anesthetist, Certified Registered median
  • Middle half of Nurse Anesthetist, Certified Registered
  • National median

In program year 2025, general payments to Meredith Sobers were reported at $1,691. Among 25,681 Nurse Anesthetist, Certified Registered profiles paid that year, the median was $46 and the middle half received between $23 and $106.

Show as a table
Year Meredith Sobers Nurse Anesthetist, Certified Registered median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $105 $34 $17–$77 $132
2022 $602 $35 $19–$82 $149
2023 $876 $38 $20–$90 $160
2024 $1,151 $42 $22–$96 $164
2025 $1,691 $46 $23–$106 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,229 61 payments
  2. AbbVie, Inc. $1,123 42 payments
  3. Ardelyx, Inc. $535 22 payments
  4. Regeneron Healthcare Solutions, Inc. $432 21 payments
  5. Janssen Biotech, Inc. $319 16 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $310 16 payments
  7. Celltrion USA Inc. $125 1 payment
  8. Intercept Pharmaceuticals, Inc. $122 6 payments
  9. Ferring Pharmaceuticals Inc. $64 2 payments
  10. Braintree Laboratories, Inc. $34 2 payments
  11. Other $132 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,425 197 payments
Products named General payments · program years 2021–2025
  1. ENTYVIO $1,139 55 payments
  2. RINVOQ $797 30 payments
  3. IBSRELA $535 22 payments
  4. SKYRIZI Immunology $403 19 payments
  5. SKYRIZI Immunology $352 11 payments
  6. DUPIXENT $316 16 payments
  7. TREMFYA $229 12 payments
  8. XIFAXAN $215 10 payments
  9. STELARA $194 10 payments
  10. ZYMFENTRA $125 1 payment
  11. Other $984 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$50,949

Medicare's payments for the services billed

Medicare patients

472

Average age 71

Services billed

485

261 women, 211 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 40%
Depression 19%
Diabetes 17%
Cancer 14%
Osteoporosis 14%
Ischemic heart disease 12%
Chronic kidney disease 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $241
$241 — —
SKYRIZI
  • AbbVie, Inc. $151
$151 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $109
  • GENZYME CORPORATION $29
$138 — —
IBSRELA
  • Ardelyx, Inc. $128
$128 — —
RINVOQ
  • AbbVie, Inc. $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Anesthetist, Certified Registered in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record